The ADRM1 (Adhesion Regulating Molecule 1) antibody targets the ADRM1 protein, also known as RPN13. a key component of the 26S proteasome involved in the ubiquitin-proteasome system (UPS). ADRM1 functions as a ubiquitin receptor, recognizing and binding polyubiquitinated substrates destined for degradation, thus playing a critical role in protein homeostasis, cell cycle regulation, and signal transduction. Structurally, ADRM1 contains an N-terminal Pru domain for ubiquitin interaction and a C-terminal KEKE motif facilitating proteasome binding. Its dysregulation is linked to cancer progression, neurodegenerative diseases, and immune disorders, making it a focus of therapeutic research. ADRM1 antibodies are widely used in techniques like Western blotting, immunoprecipitation, and immunohistochemistry to study protein expression, localization, and interactions. In cancer, elevated ADRM1 levels correlate with poor prognosis, metastasis, and drug resistance, highlighting its potential as a diagnostic marker or therapeutic target. Recent studies explore ADRM1 inhibitors, such as RA190. to disrupt proteasome activity in malignancies. Additionally, ADRM1's role in neurodegenerative conditions, like Alzheimer’s disease, underscores its importance in managing protein aggregation. These antibodies are vital tools for unraveling ADRM1's biological mechanisms and advancing targeted therapies.